Enabling manufacture and access to advanced therapy medicinal products in low- and middle-income countries. [PDF]
Campos de Carvalho AC +2 more
europepmc +1 more source
Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series. [PDF]
Svoboda MD +7 more
europepmc +1 more source
Advanced therapy medicinal products in Saudi Arabia: Regulation and development. [PDF]
AlMuhanna MH +9 more
europepmc +1 more source
Zolgensma e Atrofia Muscular Espinhal: evidências, incertezas e impacto orçamentário
Kennedy Crepalde Ribeiro +8 more
openaire +2 more sources
Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials. [PDF]
Reckelbus M +3 more
europepmc +1 more source
Newborn Screening for Spinal Muscular Atrophy in the UK: Use of Modelling to Identify Priorities for Ongoing Evaluation. [PDF]
Thokala P +6 more
europepmc +1 more source
The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions. [PDF]
Fabian D, Sehic O, Wild C.
europepmc +1 more source
Examination of the Peripheral Nervous System in Children With Spinal Muscular Atrophy: A High-Resolution Ultrasonographic Study. [PDF]
Wurster J +5 more
europepmc +1 more source
Génterápiák bemutatása farmakológiai szemmel
A génterápia a modern orvoslás egyik legintenzívebben fejlődő és legígéretesebb területe, amely lehetőséget kínál mind genetikai, mind nem genetikai betegségek oki kezelésére.
Bódi, Ádám
core
[Spinal muscular atrophy: Clinical and genetic aspects, and therapeutic alternatives]. [PDF]
González-Morales IJ +3 more
europepmc +1 more source

